Newfeed

Will initiate a first-in-human Phase 1 clinical trial for INT2104, its first-in-class in vivo targeted gene therapy, creating CAR cells for the treatment of B cell malignancies in 4Q24 PHILADELPHIA, July 9, 2024 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-speci

HONG KONG, July 9, 2024 /PRNewswire/ — Isola Capital is pleased to announce an exclusive partnership with Goldhorse Capital Management (HK) Limited (the “Goldhorse”), allowing single family offices, multi-family offices, and Ultra High Net Worth investors to access the Isola Fulle

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: